Equities

Dare Bioscience Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DARE:NAQ

Dare Bioscience Inc

Actions
  • Price (USD)1.57
  • Today's Change-0.045 / -2.80%
  • Shares traded77.24k
  • 1 Year change-48.69%
  • Beta0.9835
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

  • Revenue in USD (TTM)27.69k
  • Net income in USD-17.46m
  • Incorporated2005
  • Employees21.00
  • Location
    Dare Bioscience Inc3655 Nobel Dr Ste 260SAN DIEGO 92122-1050United StatesUSA
  • Phone+1 (858) 926-7655
  • Fax+1 (302) 636-5454
  • Websitehttps://www.darebioscience.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cellectar Biosciences Inc0.00-18.85m12.68m11.00--1.28-----10.78-10.780.002.940.00----0.00-72.62-104.57-141.24-133.43------------0.00-------4.23--33.54--
CV Sciences Inc14.37m-1.48m14.74m47.00--9.58--1.03-0.008-0.0080.0780.00841.871.6734.74305,659.60-19.21-44.92-66.32-105.3247.0442.89-10.29-49.080.2125-2.020.3829---1.87-21.80-177.18---56.43--
Hoth Therapeutics Inc0.00-12.16m15.82m2.00--1.87-----1.06-1.060.000.54420.00----0.00-138.61-129.47-154.67-144.30-----------493.480.00-------4.37------
Natural Alternatives International Inc135.16m-12.25m16.74m293.00--0.2497--0.1239-2.04-2.0422.5610.850.87364.357.80461,286.70-7.920.4593-9.610.54799.0612.75-9.060.42960.855-1.800.17870.0014.121.78-88.10---4.46--
Lexaria Bioscience Corp522.00k-10.79m17.67m7.00--3.21--33.85-0.5743-0.57430.02720.2210.0659--2.9774,571.43-136.35-102.60-145.39-105.78100.0087.95-2,069.41-1,579.38---285.300.00--52.0517.53-105.37--48.50--
Global Pharmatech Inc.3.18m-2.24m20.76m217.00--0.1459--6.53-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Dare Bioscience Inc27.69k-17.46m23.01m21.00--7.85--830.83-1.92-1.920.00290.20520.0011--0.06241,318.57-71.56-91.64-241.96-243.93127.70---63,069.55-1,024.05---156.390.7177---99.65--86.56------
TherapeuticsMD Inc2.80m73.00k25.93m1.00358.970.944756.369.270.00620.02610.24192.370.0715--0.80022,796,000.000.1867-42.650.2169-112.14----2.61-193.47---5,240.000.00--35.25-48.7269.97------
Hyperion DeFi Inc345.32k-26.40m27.54m13.00--0.329--79.74-20.32-20.320.03859.880.0065--1.0626,563.08-48.31-102.28-59.47-168.53-798.1160.58-7,385.51-856.97----0.0976--1,412.93---82.75---0.6271--
Aytu Biopharma Inc62.64m-24.56m28.34m82.00--2.00--0.4524-3.40-3.395.631.320.52592.102.22763,902.40-20.62-26.47-45.22-47.3266.8460.56-39.21-52.541.030.0570.5958--1.8419.16-13.27------
Kyntra Bio Inc8.30m-131.13m28.52m225.00------3.44-32.4953.342.05-4.210.0413-1.470.42136,880.00-64.00-39.47-260.98-61.33345.6990.21-1,548.18-199.023.60--0.5269---36.71-35.0752.60---45.94--
United-Guardian Inc10.06m1.96m29.82m24.0015.212.8214.452.960.42660.42662.192.300.79113.827.58419,180.4015.4126.9117.8531.1650.6054.1619.4826.976.16--0.0092.3411.91-2.1825.94-7.3530.65-8.64
SCYNEXIS Inc2.93m-25.30m31.44m28.00--0.863--10.72-0.5107-0.51070.05930.86830.0391--0.5776104,714.30-33.71-20.51-43.65-24.9733.32---862.89-64.82----0.00---97.3398.68-131.75------
Earth Science Tech Inc34.87m3.51m32.05m76.009.435.608.280.91910.01170.01170.11580.01965.0614.89148.30458,876.6050.5224.0476.21--73.8471.089.995.500.86065.650.0067--177.05128.98300.63------
Data as of Mar 03 2026. Currency figures normalised to Dare Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

7.41%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2025454.18k3.18%
AMH Equity Ltd.as of 30 Sep 2025232.37k1.63%
Geode Capital Management LLCas of 31 Dec 2025118.66k0.83%
G1 Execution Services LLCas of 31 Dec 202570.02k0.49%
Vanguard Fiduciary Trust Co.as of 31 Dec 202565.94k0.46%
Two Sigma Investments LPas of 31 Dec 202533.04k0.23%
SSgA Funds Management, Inc.as of 31 Dec 202523.52k0.17%
U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Dec 202520.92k0.15%
UBS Securities LLCas of 31 Dec 202520.92k0.15%
Renaissance Technologies LLCas of 31 Dec 202519.30k0.14%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.